# Standardized Photobiomodulation Dosimetry Targeting the Base of Calvarial Critical-Sized Defects for Bone Regeneration: A Preclinical RCT Comparing Flattop vs. Gaussian Beam Profiles, with or Without Bio-Oss®

**Authors:** Reem Hanna, Wayne Selting, Vincenzo Cuteri, Giacomo Rossi, Alessandro Bosco, Laura Emionite, Michele Cilli, Emanuela Marcenaro, Federico Rebaudi, Marco Greppi, Stefano Benedicenti

PMC · DOI: 10.3390/jfb17030125 · Journal of Functional Biomaterials · 2026-03-04

## TL;DR

This study shows that a new standardized 980-nm photobiomodulation (PBM) method with a flat-top beam improves bone healing in mice, especially when combined with a bone graft.

## Contribution

The first preclinical RCT to standardize PBM dosimetry for bone regeneration using flat-top vs. Gaussian beam profiles with or without Bio-Oss®.

## Key findings

- Flat-top PBM delivered more uniform and effective irradiance (1.131 W/cm²) compared to Gaussian (0.413 W/cm²).
- PBM combined with Bio-Oss® significantly accelerated bone regeneration compared to PBM alone.
- Flat-top PBM enhanced progenitor activation, osteoblast differentiation, and angiogenesis more effectively.

## Abstract

Photobiomodulation (PBM) has shown promising potential to enhance bone regeneration; however, its optimal delivery parameters and interactions with osteoconductive scaffolds remain insufficiently defined. This preclinical study is the first to incorporate a pilot dosimetry evaluation to standardize 980-nm PBM delivery and ensure that effective irradiance reached the target surface of critical-size calvarial defects in mice. The primary aim was to evaluate the effectiveness of this novel 980-nm PBM protocol delivered using either flat-top (FT) or standard Gaussian (ST) handpieces in enhancing bone regeneration in critical-size defects (CSDs), both with and without Bio-Oss® grafting. A total of 120 adult mice were allocated into twelve experimental groups (n = 10 per group): untreated (control), Bio-Oss® alone, PBM alone, and PBM combined with Bio-Oss®, using either FT or ST handpieces, and evaluated at 30 and 60 days. Animals received 980 nm irradiation at 0.6 W (nominal power output–set on laser interface) in continuous-wave mode for 60 s, three times per week, for two consecutive weeks. Pilot dosimetry included power meter measurements to determine the therapeutic power reaching the defect surface area and temperature monitoring to ensure safe energy delivery. The dosimetry study demonstrated that, after accounting for the optical properties of mouse shaved skin and the Bio-Oss® graft covered with Bio-Gide® membrane, the effective irradiance reaching the base of the defect surface area was 1.131 W/cm2 for the FT handpiece and 0.413 W/cm2 for the ST handpiece. This dose was sufficient to induce significant regenerative effects. Histological, Masson’s trichrome, and immunohistochemical analyses for Runx2, OCN, GLI1, CD34, and CTSK were performed to characterize early and late osteogenic events. The combination of PBM and Bio-Oss® significantly accelerated bone regeneration compared with PBM alone, with the FT handpiece producing the most uniform and advanced osteogenesis. PBM enhanced progenitor activation, osteoblast differentiation, angiogenesis, matrix deposition, and late-stage remodeling, demonstrating a synergistic effect with the scaffold, whereas Bio-Oss® alone or defect alone showed limited early regenerative potential. These findings highlight the effectiveness of this novel standardized PBM dosimetry and uniform beam profile (FT), supporting their use as a foundation for future randomized controlled trials in craniofacial bone repair.

## Linked entities

- **Genes:** RUNX2 (RUNX family transcription factor 2) [NCBI Gene 860], BGLAP (bone gamma-carboxyglutamate protein) [NCBI Gene 632], GLI1 (GLI family zinc finger 1) [NCBI Gene 2735], CD34 (CD34 molecule) [NCBI Gene 947], CTSK (cathepsin K) [NCBI Gene 1513]
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Cd34 (CD34 antigen) [NCBI Gene 12490], Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, Ctsk (cathepsin K) [NCBI Gene 13038] {aka MMS10-Q, Ms10q, catK}, Hc (hemolytic complement) [NCBI Gene 15139] {aka C5, C5a, He, Hfib2}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 22339] {aka L-VEGF, Vegf, Vpf}, Gli1 (GLI-Kruppel family member GLI1) [NCBI Gene 14632] {aka Zfp-5, Zfp5}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, Vtn (vitronectin) [NCBI Gene 22370] {aka Vn}, Ctnnb1 (catenin beta 1) [NCBI Gene 12387] {aka Bfc, Catnb, Mesc}, Fn1 (fibronectin 1) [NCBI Gene 14268] {aka E330027I09, Fn, Fn-1}, Bglap2 (bone gamma-carboxyglutamate protein 2) [NCBI Gene 12097] {aka BGP2, Bglap1, Bgp, Og2, mOC-B}, Mapk1 (mitogen-activated protein kinase 1) [NCBI Gene 26413] {aka 9030612K14Rik, ERK, Erk2, MAPK2, PRKM2, Prkm1}, Runx2 (runt related transcription factor 2) [NCBI Gene 12393] {aka AML3, CBF-alpha-1, Cbf, Cbfa-1, Cbfa1, LS3}
- **Diseases:** respiratory distress (MESH:D012128), cranial deformities (MESH:D003389), bone tissue defects (MESH:D018213), diabetes mellitus (MESH:D003920), unconsciousness (MESH:D014474), inflammation (MESH:D007249), rheumatoid arthritis (MESH:D001172), dural perforation (MESH:D057112), osteoporosis (MESH:D010024), pain (MESH:D010146), wound dehiscence (MESH:D013529), reduced bone density (MESH:D001851), CSD (MESH:C562576), systemic illness (MESH:D012140), calvarial defect (MESH:C537963), weight loss (MESH:D015431), tumor (MESH:D009369), Death (MESH:D003643), Bone Defect (MESH:D001847), dislocation (MESH:D004204), congenital malformations (OMIM:163000), infection (MESH:D007239), bleeding (MESH:D006470), injury to (MESH:D014947)
- **Chemicals:** EDTA (MESH:D004492), biotin (MESH:D001710), polyglycolic acid (MESH:D011100), water (MESH:D014867), formic acid (MESH:C030544), xylene (MESH:D014992), hydrochloric acid (MESH:D006851), hydroxyapatite (MESH:D017886), Eosin (MESH:D004801), Hematoxylin (MESH:D006416), carbon dioxide (MESH:D002245), ATP (MESH:D000255), DAB (MESH:C000469), Bio-Oss (MESH:C077540), Triton X-100 (MESH:D017830), ethanol (MESH:D000431), TBS (MESH:D013725), citrate (MESH:D019343), formalin (MESH:D005557), Isoflurane (MESH:D007530), Alexa Fluor 594 (-), paraffin (MESH:D010232), ROS (MESH:D017382), xylazine (MESH:D014991)
- **Species:** Homo sapiens (human, species) [taxon 9606], Bos taurus (bovine, species) [taxon 9913], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** BALB/c — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0184)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13028131/full.md

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13028131/full.md

## References

98 references — full list in the complete paper: https://tomesphere.com/paper/PMC13028131/full.md

---
Source: https://tomesphere.com/paper/PMC13028131